March 22, 2004

News Release: MedMira Ships 100,000 Rapid HIV Test Kits to China, First of 1.3 Million Kit Order

MedMira Inc. ('MedMira') (TSX Venture: MIR) today announced that the company has completed an initial shipment of 100,000 MiraWell(TM) Rapid HIV Tests to the People's Republic of China. The shipment is the first portion of an annual commitment of 1.3 million kits from a new distributor, which replaces the agreement previously announced with Long Hao Healthcare Technology Company Ltd., of Guangzhou, China. This marks the first Canadian commercially available Rapid HIV test to ever be shipped to China.

The new distributor is highly experienced in the distribution of medical products and devices. This agreement covers the 8 provinces they serve in southwestern and northeastern China. 'The China market is a difficult one with many complex distribution channels and it has taken several months of active work to achieve the type of business arrangements we sought,'said Stephen Sham, MedMira chairman and CEO, 'but with this new contract, volumes are substantial, and we have a strong start in opening the entire China market for MedMira products.'

MedMira (www.medmira.com) is a commercial biotechnology company that develops, manufactures and markets qualitative, in vitro diagnostic tests for the detection of antibodies to certain diseases, such as HIV, in human serum, plasma or whole blood. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) and MiraWell(TM) Rapid HIV Tests, respectively.

All of MedMira's diagnostic tests are based on the same flow-through technology platform, thus facilitating the development of future products. MedMira's technology provides a quick (under 3 minutes), accurate, portable, safe and cost-effective alternative to conventional laboratory testing.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

SOURCE MedMira Inc.

Dr. James Smith: (902) 450-1588 or e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. (MIR.)

WEBSITE EMAIL